|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBOX5 |
Gene summary for UBOX5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBOX5 | Gene ID | 22888 |
| Gene name | U-box domain containing 5 | |
| Gene Alias | RNF37 | |
| Cytomap | 20p13 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | O94941 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22888 | UBOX5 | LZE4T | Human | Esophagus | ESCC | 1.59e-02 | 9.99e-02 | 0.0811 |
| 22888 | UBOX5 | P2T-E | Human | Esophagus | ESCC | 5.42e-04 | 8.95e-02 | 0.1177 |
| 22888 | UBOX5 | P4T-E | Human | Esophagus | ESCC | 3.68e-03 | 7.01e-02 | 0.1323 |
| 22888 | UBOX5 | P8T-E | Human | Esophagus | ESCC | 1.68e-05 | 7.05e-02 | 0.0889 |
| 22888 | UBOX5 | P9T-E | Human | Esophagus | ESCC | 3.46e-04 | 8.37e-02 | 0.1131 |
| 22888 | UBOX5 | P10T-E | Human | Esophagus | ESCC | 4.79e-06 | 1.19e-01 | 0.116 |
| 22888 | UBOX5 | P11T-E | Human | Esophagus | ESCC | 4.08e-04 | 1.52e-01 | 0.1426 |
| 22888 | UBOX5 | P12T-E | Human | Esophagus | ESCC | 3.97e-08 | 1.50e-01 | 0.1122 |
| 22888 | UBOX5 | P15T-E | Human | Esophagus | ESCC | 1.50e-05 | 1.30e-01 | 0.1149 |
| 22888 | UBOX5 | P16T-E | Human | Esophagus | ESCC | 5.74e-10 | 1.55e-01 | 0.1153 |
| 22888 | UBOX5 | P17T-E | Human | Esophagus | ESCC | 1.24e-02 | 1.64e-01 | 0.1278 |
| 22888 | UBOX5 | P20T-E | Human | Esophagus | ESCC | 9.71e-05 | 1.11e-01 | 0.1124 |
| 22888 | UBOX5 | P21T-E | Human | Esophagus | ESCC | 3.96e-05 | 1.26e-01 | 0.1617 |
| 22888 | UBOX5 | P22T-E | Human | Esophagus | ESCC | 5.05e-03 | 4.40e-02 | 0.1236 |
| 22888 | UBOX5 | P23T-E | Human | Esophagus | ESCC | 2.55e-09 | 1.75e-01 | 0.108 |
| 22888 | UBOX5 | P24T-E | Human | Esophagus | ESCC | 3.67e-04 | 9.56e-02 | 0.1287 |
| 22888 | UBOX5 | P26T-E | Human | Esophagus | ESCC | 3.68e-28 | 4.88e-01 | 0.1276 |
| 22888 | UBOX5 | P28T-E | Human | Esophagus | ESCC | 4.16e-02 | 9.78e-02 | 0.1149 |
| 22888 | UBOX5 | P30T-E | Human | Esophagus | ESCC | 2.59e-03 | 2.19e-01 | 0.137 |
| 22888 | UBOX5 | P31T-E | Human | Esophagus | ESCC | 6.77e-06 | 1.63e-01 | 0.1251 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
| GO:000020921 | Liver | HCC | protein polyubiquitination | 151/7958 | 236/18723 | 1.90e-11 | 7.59e-10 | 151 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
| hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBOX5 | SNV | Missense_Mutation | c.1294N>A | p.Glu432Lys | p.E432K | O94941 | protein_coding | deleterious(0.01) | benign(0.272) | TCGA-A2-A0YD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| UBOX5 | SNV | Missense_Mutation | c.676C>G | p.Pro226Ala | p.P226A | O94941 | protein_coding | deleterious(0.03) | benign(0.427) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| UBOX5 | insertion | Frame_Shift_Ins | novel | c.1050_1051insTTTCTTTTTGTTTTGTTTTTTTGGAAACAGT | p.Ala351PhefsTer30 | p.A351Ffs*30 | O94941 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
| UBOX5 | insertion | In_Frame_Ins | novel | c.1109_1110insCAAATTGCAATATTCTCTTTGTGTTTT | p.Glu370delinsAspLysLeuGlnTyrSerLeuCysValLeu | p.E370delinsDKLQYSLCVL | O94941 | protein_coding | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| UBOX5 | insertion | In_Frame_Ins | novel | c.1107_1108insAAATGTGTG | p.Ala369_Glu370insLysCysVal | p.A369_E370insKCV | O94941 | protein_coding | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| UBOX5 | insertion | Nonsense_Mutation | novel | c.552_553insTACACTTCTCCAGTGTGCTCTGGTCGATGACCTTGCCTCGGCTTCCTAAAGTGCTGGGATCGGT | p.Ile185TyrfsTer10 | p.I185Yfs*10 | O94941 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| UBOX5 | insertion | Frame_Shift_Ins | novel | c.803_804insTT | p.Leu269SerfsTer43 | p.L269Sfs*43 | O94941 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| UBOX5 | SNV | Missense_Mutation | novel | c.1612N>T | p.Arg538Trp | p.R538W | O94941 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UBOX5 | SNV | Missense_Mutation | novel | c.641N>T | p.Ser214Leu | p.S214L | O94941 | protein_coding | deleterious(0.01) | possibly_damaging(0.576) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| UBOX5 | SNV | Missense_Mutation | c.341N>T | p.Ala114Val | p.A114V | O94941 | protein_coding | tolerated(0.22) | benign(0.085) | TCGA-FU-A2QG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |